Aj. Sleight et al., RADIOLABELING OF THE HUMAN 5-HT2A RECEPTOR WITH AN AGONIST, A PARTIALAGONIST AND AN ANTAGONIST - EFFECTS ON APPARENT AGONIST AFFINITIES, Biochemical pharmacology, 51(1), 1996, pp. 71-76
Previous work has shown that 5-hydroxytryptamine (5-HT)(2A) receptors
can be radiolabelled with various radioligands, including partial agon
ists, such as [I-125]-DOI and [H-3]-DOB, and antagonists, such as [H-3
]-ketanserin and [H-3]-spiperone. Because 5-HT has high affinity for t
he 5-HT2A receptor when displacing [H-3]-DOB, the purpose of the prese
nt study was to determine whether or not the receptor could be labelle
d with [H-3]-5-HT and what would be the effect of labelling the recept
or with various radioligands having differing efficacies at the recept
or. Consequently, the human 5-HT2A receptor stably expressed in NIH 3T
3 cells was radiolabelled with the endogenous agonist [H-3]-5-HT, the
partial agonist [H-3]-DOB, and the antagonist [H-3]-ketanserin. The re
ceptor could be radiolabelled with [H-3]-5-HT with a K-d value of 1.3
+/- 0.1 nM and a B-max value of 3461 +/- 186 fmoles/mg protein and the
radiolabelling was sensitive to the stable guanosine 5'-triphosphate
(GTP) analogue guanylyl-imidodiphosphate (GMP-PNP). Ketanserin labeled
significantly more receptors (K-d = 1.1 +/- 0.1 nM: B-max = 27684 +/-
1500 fmoles/mg protein) than [H-3]-DOB (K-d = 0.8 +/- 0.08 nM: B-max
= 8332 +/- 16 fmoles/mg protein) which, in rum, labelled significantly
more receptors than [H-3]-5-HT. The apparent affinity of antagonists
did not change when the receptor was radiolabelled with either [H-3]-a
gonists or [H-3]-antagonists; however, agonists had a higher apparent
affinity for [H-3]-agonist-labeled receptors than for [H-3]-antagonist
-labeled receptors. Therefore, the apparent affinity of agonists for t
he 5-HT2A receptor estimated from displacement experiments depends on
the intrinsic efficacy of the radioligand used.